Opus Genetics reports FY2024 net loss of $57.5M; gene therapy pipeline advances

Opus Genetics, Inc.

2025-Q1 EPS reported -$0.24 revenue$4,370,000

Net loss of $57.5M ($2.15/sh) vs $10.0M in 2023; revenue $11M from Viatris license.
Cash $30.3M at year-end; March 2025 financing raised $21.5M, extending runway into H2 2026.
OPGx-LCA5 Phase 1/2 shows durable response at 12 months; Type D FDA meeting held; pediatric enrollment started.
OPGx-BEST1 IND-enabling studies done; Phase 1/2 initiation planned for 2025 with preliminary data by Q1 2026.
Phentolamine LYNX-2 (dim light) and VEGA-3 (presbyopia) Phase 3 trials fully enrolled; topline data expected mid-2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.